Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 174 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

 		Hidradenitis Suppurativa (HS) Phase4 China NCT07489573

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

 		Hypertension (HTN) Phase2 Singapore
United States 		NCT07543120

A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis

 		Dermatitis, Atopic Phase1 Japan NCT07604324

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

 		Advanced HR+/HER2- Breast Cancer Phase1 Singapore
United States 		NCT07604571

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

 		Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase1, Phase2 Singapore
United States 		NCT07564401

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

 		Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease Switzerland NCT07517250

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

 		Leukemia, Chronic Myeloid Germany NCT07549516

Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment

 		Advanced Malignancies and Hepatic Impairment Phase1 Italy
United Kingdom 		NCT07422610

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

 		Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase1 Australia
United States 		NCT07570979

Remibrutinib Open Label Roll-over Post-trial Access Protocol

 		Indication of the Parent Protocol Phase3 Canada
South Korea 		NCT07456891